Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis

Objective To examine the risk of diabetes mellitus (DM) among subjects with rheumatoid arthritis (RA), psoriatic arthritis or psoriasis (PsA/PsO), compared with non-rheumatic controls. Methods Study cohorts were assembled using linked healthcare utilisation data from British Columbia. All people with at least two diagnoses of RA or PsA/PsO were included and compared with a cohort of people without any known rheumatic disease. The outcome of interest was a diagnosis of new-onset DM, as defined by initiation of an antidiabetic drug. Incidence rates (IRs) per 1000 person-years and IR ratios were calculated and Cox regression models were constructed to determine the hazard ratio (HR) for diabetes by age, gender, systemic immunosuppressive drug and glucocorticoid use. Results The study cohort comprised 48 718 subjects with RA, 40 346 with PsA/PsO and 442 033 without any rheumatic disease. The IR for DM among subjects with RA was 8.6 per 1000 person-years (95% CI 8.5 to 8.7), PsA/PsO 8.2 (95% CI 8.1 to 8.3) and for non-rheumatic controls 5.8 (95% CI 5.8 to 5.8). The adjusted HR for RA compared with non-rheumatic controls was 1.5 (95% CI 1.4 to 1.5) and 1.4 (95% CI 1.3 to 1.5) for PsA/PsO. Conclusions RA and PsA/PsO appear to be associated with an increased risk of DM. The ability of potent antirheumatic treatments to reverse this trend warrants study.

[1]  A. Qureshi,et al.  Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. , 2009, Archives of dermatology.

[2]  M. Matsuda,et al.  Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction , 2009, Clinical Rheumatology.

[3]  Chun-Ying Wu,et al.  Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. , 2008, Archives of dermatology.

[4]  S. Jick,et al.  Psoriasis and the risk of incident diabetes mellitus: a population‐based study , 2008, The British journal of dermatology.

[5]  T. Pincus,et al.  Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. , 2008, Arthritis and rheumatism.

[6]  S. Gabriel,et al.  Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? , 2007, Annals of the rheumatic diseases.

[7]  J. Fries,et al.  Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. , 2007, JAMA.

[8]  Anna Viner,et al.  The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. , 2007, Journal of the American Academy of Dermatology.

[9]  M. Bala,et al.  Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. , 2006, The Journal of rheumatology.

[10]  Daniel B. Shin,et al.  Prevalence of cardiovascular risk factors in patients with psoriasis. , 2022, Central European journal of public health.

[11]  Daniel B. Shin,et al.  Risk of myocardial infarction in patients with psoriasis. , 2006, JAMA.

[12]  J. Avorn,et al.  Patterns of cardiovascular risk in rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[13]  Stefania Favilla,et al.  Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes. , 2006, Diabetes.

[14]  R. D'Agostino,et al.  Hemostatic markers of endothelial dysfunction and risk of incident type 2 diabetes: the Framingham Offspring Study. , 2006, Diabetes.

[15]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[16]  S. Gabriel,et al.  Cardiovascular death in rheumatoid arthritis: a population-based study. , 2005, Arthritis and rheumatism.

[17]  P. Savage,et al.  Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. , 2004, Diabetes.

[18]  Michele Muggeo,et al.  Population-based incidence rates and risk factors for type 2 diabetes in white individuals: the Bruneck study. , 2004, Diabetes.

[19]  R. Tamblyn,et al.  Validation of diagnostic codes within medical services claims. , 2004, Journal of clinical epidemiology.

[20]  U. Smith,et al.  Interleukin-6 (IL-6) Induces Insulin Resistance in 3T3-L1 Adipocytes and Is, Like IL-8 and Tumor Necrosis Factor-α, Overexpressed in Human Fat Cells from Insulin-resistant Subjects* , 2003, Journal of Biological Chemistry.

[21]  T. Zimmers,et al.  Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. , 2003, Diabetes.

[22]  JoAnn E. Manson,et al.  Cardiovascular Morbidity and Mortality in Women Diagnosed With Rheumatoid Arthritis , 2003, Circulation.

[23]  Janet E Hux,et al.  Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. , 2002, Diabetes care.

[24]  G L Freeman,et al.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. , 2001, Arthritis and rheumatism.

[25]  S. Gabriel,et al.  The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. , 1999, Arthritis and rheumatism.

[26]  R. Tisch,et al.  Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process , 1994, The Journal of experimental medicine.

[27]  J. Jollis,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.

[28]  K J Rothman,et al.  A strengthening programme for weak associations. , 1988, International journal of epidemiology.